Despite an expected dip in profit, analysts are generally optimistic about Pfizer as it prepares to reports its first-quarter earnings on Tuesday, April 28, 2015. The consensus earnings per share estimate is 50 cents per share.
The consensus estimate hasn't changed over the past month, but it's down from three months ago when it was 51 cents. For the fiscal year, analysts are projecting earnings of $2.07 per share. After being $11.35 billion a year ago, analysts project revenue to drop 5% year-over-year to $10.73 billion for the quarter. For the year, revenue is projected to roll in at $45.96 billion.
A year-over-year revenue increase in the fourth quarter snapped a streak of two consecutive quarters of revenue declines.
Over the last four quarters, revenue has fallen an average of 1% year-over-year. The biggest drop came in the first quarter, when revenue fell 16% from the year-earlier quarter.
The majority of analysts (62%) rate Pfizer as a buy. This compares favorably to the analyst ratings of 10 similar companies, which average 55% buys.
Earnings estimates provided by Zacks.
Narrative Science, through its proprietary artificial intelligence platform, transforms data into stories and insights.
